Repinotan kit

Abstract

The invention relates to a kit comprising a pharmaceutical composition containing repinotan or a physiologically acceptable salt of repinotan, and a means for the determination of the concentration of repinotan or its metabolites in body fluids, and also new pharmaceutical compositions containing repinotan or a physiologically acceptable salt of repinotan, and processes for their preparation.

1 . Kit comprising 
 a) a pharmaceutical composition containing repinotan and/or a physiologically acceptable salt of repinotan, and    b) an agent for the determination of the concentration of repinotan or its metabolites in body fluids.    
     
     
         2 . Kit according to  claim 1 , where the pharmaceutical composition contains repinotan hydrochloride.  
     
     
         3 . Kit according to  claim 1  or  2 , where the kit comprises an agent for determination of the concentration of the analyte in blood or in fractions obtained from blood.  
     
     
         4 . Kit according to  claim 3 , where the kit comprises an agent for determination of the concentration of the analyte in blood plasma.  
     
     
         5 . Kit according to one of  claims 1  to  4 , where the agent operates according to an immunological process.  
     
     
         6 . Kit according to one of  claims 1  to  5 , where the agent means can be employed at the site of treatment.  
     
     
         7 . Kit according to one of  claims 1  to  6  for the acute treatment of neurodegenerative diseases.  
     
     
         8 . Kit according to one of  claims 1  to  6  for the acute treatment of stroke or craniocerebral trauma.  
     
     
         9 . Solid pharmaceutical composition containing repinotan or a physiologically acceptable salt of repinotan, and a physiologically acceptable acid.  
     
     
         10 . Composition according to  claim 9 , where the proportion by weight of the active compound is 0.01-15% by weight and the proportion by weight of the acid is 0.5-15% by weight.  
     
     
         11 . Composition according to  claim 9  or  10 , where the composition contains repinotan hydrochloride as the active compound and citric acid or tartaric acid as the acid.  
     
     
         12 . Process for the preparation of a composition according to one of  claims 9  to  11 , where the active compound, the acid and further pharmaceutical excipients are dissolved in water and/or other suitable solvents, the solution is optionally rendered sterile and the solution is then lyophilized.  
     
     
         13 . Composition obtainable according to the process as in  claim 12 .  
     
     
         14 . Infusion solution containing repinotan or a physiologically acceptable salt of repinotan, and one or more acids selected from the group consisting of malic acid, pyruvic acid, citric acid, fumaric acid, maleic acid, lactic and tartaric acid.  
     
     
         15 . Infusion solution according to  claim 14 , where the acid is citric acid or tartaric acid.  
     
     
         16 . Process for the preparation of an infusion solution containing repinotan or a physiologically acceptable salt of repinotan, and one or more acids selected from the group consisting of malic acid, pyruvic acid, citric acid, fumaric acid, maleic acid, lactic acid and tartaric acid, where water or an isotonic electrolyte solution is added to a composition as in  claim 13 .  
     
     
         17 . Infusion solution obtainable according to the process as in  claim 16 .  
     
     
         18 . Use of compositions according to  claim 13  for the preparation of infusion solutions.  
     
     
         19 . Compound of the formula